NSCLC Education Center Disease State Hub

Non-Small Cell Lung Cancer

Education Center

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

Conference Coverage

Adagrasib Improves Response Among Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

09/25/2024

Stephanie Holland ;

According to exploratory results from the phase 3 KRYSTAL-12 trial, adagrasib improved efficacy outcomes among patients with previously treated KRAS G12C-mutated advanced non-small cell lung cancer, regardless of the presence of baseline...

According to exploratory results...

09/25/2024

Oncology

Conference Coverage

Biomarkers With Alectinib for ALK-Positive Non-Small Cell Lung Cancer

09/10/2024

Allison Casey ;

According to exploratory biomarker analyses from the phase 3 ALINA trial, there was a benefit to disease-free survival with alectinib regardless of EML4-ALK variant among patients with NSCLC.

According to exploratory...

09/10/2024

Oncology

News

Vebreltinib Demonstrated Promising Efficacy, Safety Among Patients With Advanced METex14-Mutant Non-Small Cell Lung Cancer

08/22/2024

Stephanie Holland ;

Results from the phase 2 KUNPENG trial demonstrated that vebreltinib showed promising efficacy and safety among patients with locally advanced or metastatic METex14-mutant non-small cell lung cancer.

Results from the phase 2 KUNPENG...

08/22/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

Conference Coverage

Adagrasib Improved Survival and Response Among Patients With KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

06/17/2024

Tony Mok, MD

According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.

According to results from the...

06/17/2024

Oncology

Conference Coverage

Lorlatinib Provides Longest Progression Free Survival Ever Seen for Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer

06/02/2024

Allison Casey

According to updated data presented at the 2024 ASCO Annual Meeting, lorlatinib has provided the longest progression-free survival ever reported among patients with advanced ALK-positive non-small cell lung cancer.

According to updated data...

06/02/2024

Oncology

News

Adjuvant Durvalumab Efficacy for Non-Small Cell Lung Cancer With Mutations

05/10/2023

Derek Cowsert ;

A study explored the efficacy of adjuvant durvalumab for patients with stage 3 unresectable non-small cell lung cancer and KRAS mutations, as well as uncommon driver genomic alterations.

A study explored the efficacy of...

05/10/2023

Oncology

Recent News

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

Conference Coverage

Adagrasib Improves Response Among Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

09/25/2024

Stephanie Holland ;

According to exploratory results...

09/25/2024

Oncology

Conference Coverage

Biomarkers With Alectinib for ALK-Positive Non-Small Cell Lung Cancer

09/10/2024

Allison Casey ;

According to exploratory biomarker analyses from the phase 3 ALINA trial, there was a benefit to disease-free survival with alectinib regardless of EML4-ALK variant among patients with NSCLC.

According to exploratory...

09/10/2024

Oncology

News

Vebreltinib Demonstrated Promising Efficacy, Safety Among Patients With Advanced METex14-Mutant Non-Small Cell Lung Cancer

08/22/2024

Stephanie Holland ;

Results from the phase 2 KUNPENG trial demonstrated that vebreltinib showed promising efficacy and safety among patients with locally advanced or metastatic METex14-mutant non-small cell lung cancer.

Results from the phase 2 KUNPENG...

08/22/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

Conference Coverage

Lorlatinib Provides Longest Progression Free Survival Ever Seen for Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer

06/02/2024

Allison Casey

According to updated data...

06/02/2024

Oncology

News

Adjuvant Durvalumab Efficacy for Non-Small Cell Lung Cancer With Mutations

05/10/2023

Derek Cowsert ;

A study explored the efficacy of adjuvant durvalumab for patients with stage 3 unresectable non-small cell lung cancer and KRAS mutations, as well as uncommon driver genomic alterations.

A study explored the efficacy of...

05/10/2023

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology